drug · small molecule
treprostinil SR
Phase 3updated 6mo agoby $LQDA Liquidia Corp🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 6Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for recurrent thrombophlebitis and pulmonary arterial hypertension and 16 investigational indications.
targets
Prostacyclin receptor
all catalysts(0)
nothing on the calendar yet
Trials studying treprostinil SR
- phase3An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase3An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
- phase4Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
- phase3Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase3Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
- phase4A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
- phase1A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- phase2A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
News(8)
- Roivant, the 'inveterate drug hunters', enters commercial era with LisrayaCEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.biospace · 1mo ago
- Roivant's pulmonary hypertension drug shines with ‘blowout’ Phase 2 dataMosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, 'significantly exceeded expectations' in reducing pulmonary vascular resistance, according to analysts, and is progressing…biospace · 2mo ago
- Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 winRoivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study.fiercebiotech · 2mo ago
- FDA extends review of Capricor cell therapy; Pain drug startup to go publicThe agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.biopharma_dive · 2mo ago
- Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesThe new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched…biopharma_dive · 4mo ago
- Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilityInsmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements thro…biospace · 4mo ago
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 4mo ago
- Avalyn, in pursuit of better lung drugs, banks $300M in an IPOThe biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.biopharma_dive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that